UPDATE: Goldman Sachs Downgrades Acadia Pharmaceuticals (ACAD) to Sell
Tweet Send to a Friend
(Updated - November 4, 2022 6:10 AM EDT)
Goldman Sachs analyst Salveen Richter downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Salveen Richter downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
